

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Mydecine Innovations Group Inc. (the “Company”)
Suite 810 – 789 West Pender Street
Vancouver, BC V6C 1H2

Item 2 Date of Material Change

June 9, 2022

Item 3 News Release

A news release was disseminated on June 9, 2022 through the facilities of Cision and subsequently filed on SEDAR.

Item 4 Summary of Material Change

The Company announced the appointment of Todd Heinzl to its board of directors to replace Independent Director, Gordon Neal.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

On June 9, 2022, the Company announced the appointment of Todd Heinzl to its board of directors to replace Independent Director, Gordon Neal. Mr. Heinzl holds over 30 years of experience in the investment, merchant banking, and financial services industry. Mr. Heinzl’s expertise centers around assisting globally minded small and mid-cap companies by developing adequate corporate governance policies.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not applicable.

Item 8 Executive Officer

David Joshua Bartch,
Chief Executive Officer
604-687-2038
jbartch@mydecineinc.com

Item 9 Date of Report

August 29, 2022